Log in to save to my catalogue

Post-registration experience of nivolumab in advanced hepatocellular carcinoma: an international stu...

Post-registration experience of nivolumab in advanced hepatocellular carcinoma: an international stu...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_a6f7c74dd48f4d2982a8f93cab08e973

Post-registration experience of nivolumab in advanced hepatocellular carcinoma: an international study

About this item

Full title

Post-registration experience of nivolumab in advanced hepatocellular carcinoma: an international study

Publisher

England: BMJ Publishing Group Ltd

Journal title

Journal for immunotherapy of cancer, 2020-08, Vol.8 (2), p.e001033

Language

English

Formats

Publication information

Publisher

England: BMJ Publishing Group Ltd

More information

Scope and Contents

Contents

BackgroundNivolumab is Food and Drug Administration approved in sorafenib-experienced, advanced hepatocellular carcinoma (HCC). Post-registration data of treatment in a real-world setting is lacking.Patients and methodsWe performed an international, multicenter observational study to confirm safety and efficacy of nivolumab in 233 patients treated...

Alternative Titles

Full title

Post-registration experience of nivolumab in advanced hepatocellular carcinoma: an international study

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_doaj_primary_oai_doaj_org_article_a6f7c74dd48f4d2982a8f93cab08e973

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_a6f7c74dd48f4d2982a8f93cab08e973

Other Identifiers

ISSN

2051-1426

E-ISSN

2051-1426

DOI

10.1136/jitc-2020-001033

How to access this item